Results 91 to 100 of about 85,538 (123)

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results From the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME) [PDF]

European Urology, 2019
The European Organisation for Research and Treatment of Cancer SURTIME trial explored timing of sunitinib, a tyrosine kinase inhibitor (TKI), and cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma. Previous retrospective studies suggest increased surgery-related adverse events (AEs) after presurgical TKI. We report surgical
John B A G Haanen, Thomas Powles, Peter Mulders   +2 more
exaly   +11 more sources

Some of the next articles are maybe not open access.

Related searches:

Deferred Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Urologic Oncology: Seminars and Original Investigations, 2023
Deferred cytoreductive nephrectomy (dCN) after upfront systemic therapy has been utilized in the management of select patients with metastatic renal cell carcinoma (mRCC). Herein, we sought to review the current evidence and define oncologic and perioperative outcomes associated with deferred surgical management of newly diagnosed mRCC.
Christopher J. D. Wallis, Bimal Bhindi, Jack R Andrews   +2 more
exaly   +3 more sources

The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Cancers, 2023
The role of cytoreductive nephrectomy in metastatic renal cell carcinoma (RCC) has been studied intensively over the past few decades. Interestingly, the opinion with regard to the importance of this procedure has switched from a recommendation as a ...
Vladimír Študent, Bohuslav Melichar, Hana Študentová   +2 more
exaly   +2 more sources

Deferred Cytoreductive Nephrectomy in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma

European Urology, 2020
The use of cytoreductive nephrectomy (CN) selectively for patients who show a favorable response to upfront systemic therapy may be an approach to select optimal candidates with metastatic renal cell carcinoma (mRCC) who are most likely to benefit.We sought to characterize outcomes of deferred CN (dCN) after upfront sunitinib, outcomes relative to ...
Daniel Heng, Brian Rini, Ravindran Kanesvaran   +2 more
exaly   +5 more sources

Cytoreductive Surgery, Systemic Treatment, Genetic Evaluation, and Patient Perspective in a Young Adult With Metastatic Renal Cell Carcinoma

Ca-A Cancer Journal for Clinicians
CA: A Cancer Journal for Clinicians, Volume 74, Issue 4, Page 323-338, July/August 2024.
Kenneth Ogan, Mani A Daneshmand, Shishir Maithel   +2 more
exaly   +2 more sources

Differences in the exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomized controlled trial SURTIME.

Journal of Clinical Oncology, 2020
703 Background: SURTIME compared immediate CN followed by sunitinib 50mg/day (4/2 weeks on-off) 4 weeks after surgery (n=50) versus 3 cycles sunitinib followed by CN in the absence of progression and continued sunitinib 4 weeks after surgery (n=49).
Yasmin Abu-Ghanem, Johannes V. Van Thienen, Christian U. Blank, Thomas Powles, Bertrand F. TOMBAL, Laurence Collette, John B. A. G. Haanen, Axel Bex   +7 more
openaire   +1 more source

Deferred Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Patient-Level Meta-Analysis

Urologic Oncology: Seminars and Original Investigations
There has been much controversy regarding the order in which cytoreductive nephrectomy (CN) and systemic therapy (ST) are applied for patients with metastatic renal cell carcinoma (mRCC). We aimed to investigate the role of deferred CN (dCN) in mRCC, particularly in the current era of immunotherapy.
Kenneth Chen, Ee Jean Lim, Valerie Huei Li Gan   +2 more
exaly   +3 more sources

Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real-World Multicenter Retrospective Study

International Journal of Urology
ABSTRACT Objective The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) remains controversial in the era of modern systemic therapy. We aimed to evaluate the proportion of patients undergoing deferred CN (dCN) and their oncological outcomes in a real‐world ...
Shin Kobayashi, Shingo Hatakeyama, Hirotake Kodama   +2 more
exaly   +3 more sources

Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.

Journal of Clinical Oncology, 2019
4578 Background: While the CARMENA trial prompts more caution with upfront cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC), 17% of patients in the sunitinib alone arm underwent deferred CN (dCN). Upfront systemic therapy has been proposed as a potential litmus test to identify patients suitable for CN, but data ...
Bhindi, Bimal, Graham, Jeffrey, Wells, Connor, Donskov, Frede, Pasini, Felice, Lee, Jae-Lyun, Basappa, Naveen S., Hansen, Aaron Richard, Wood, Lori, Kollmannsberger, Christian K., Kanesvaran, Ravindran, Yuasa, Takeshi, Ernst, D. Scott, Srinivas, Sandy, Rini, Brian I., Bowman, I. Alex, Pal, Sumanta K., Choueiri, Toni K., Heng, Daniel Yick Chin   +18 more
openaire   +2 more sources

Impact of systemic therapy (ST) on deferred cytoreductive nephrectomy (CN) perioperative outcomes: A National Surgical Quality Improvement Program (NSQIP) analysis.

Journal of Clinical Oncology, 2023
650 Background: Management of metastatic renal cell carcinoma (mRCC) is highly individualized and often involves cytoreductive nephrectomy (CN) and systemic therapy (ST). The optimal sequencing of CN and ST is uncertain. A difference in perioperative outcomes based on sequence of CN and ST could influence decision-making.
Shawn Dason, Tyler Sheetz, Shagnik Ray, Danielle Elise Zimmerman, Ming Yin, Edmund Folefac, Amir Mortazavi, Michael Gong, Ahmad Shabsigh, Eric A. Singer   +9 more
openaire   +1 more source